NCT06611436View on ClinicalTrials.gov

BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 4, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Hemophilia BHemophilia B, Moderately Severe or Severe
Interventions
DRUG

BE-101

IV Infusion of BE-101 dose from Dose Level 1

DRUG

BE-101

IV Infusion of BE-101 dose from Dose Level 2

DRUG

BE-101

IV Infusion of BE-101 dose from Dose Level 3

DRUG

BE-101

IV Infusion of BE-101 with optimal dose selected from Part 1 Dose Escalation

Trial Locations (4)

48109

RECRUITING

University of Michigan, Ann Arbor

55455

RECRUITING

University of Minnesota, Minneapolis

95616

RECRUITING

University of California, Davis, Davis

98101

RECRUITING

Washington Center for Bleeding Disorders, Seattle

Sponsors

Lead Sponsor

Be Biopharma
All Listed Sponsors
lead

Be Biopharma

INDUSTRY

NCT06611436 - BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia B | Biotech Hunter | Biotech Hunter